Stoke Therapeutics (STOK) Shares Outstanding (Weighted Average) (2022 - 2025)
Stoke Therapeutics has reported Shares Outstanding (Weighted Average) over the past 4 years, most recently at $59.2 million for Q4 2025.
- Quarterly results put Shares Outstanding (Weighted Average) at $59.2 million for Q4 2025, up 9.65% from a year ago — trailing twelve months through Dec 2025 was $59.2 million (up 9.65% YoY), and the annual figure for FY2025 was $59.2 million, up 9.65%.
- Shares Outstanding (Weighted Average) for Q4 2025 was $59.2 million at Stoke Therapeutics, up from $58.6 million in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for STOK hit a ceiling of $59.2 million in Q4 2025 and a floor of $37.4 million in Q1 2022.
- Median Shares Outstanding (Weighted Average) over the past 4 years was $45.2 million (2023), compared with a mean of $47.9 million.
- Biggest five-year swings in Shares Outstanding (Weighted Average): increased 8.72% in 2024 and later increased 25.12% in 2025.
- Stoke Therapeutics' Shares Outstanding (Weighted Average) stood at $38.9 million in 2022, then rose by 13.1% to $44.0 million in 2023, then increased by 22.76% to $54.0 million in 2024, then rose by 9.65% to $59.2 million in 2025.
- The last three reported values for Shares Outstanding (Weighted Average) were $59.2 million (Q4 2025), $58.6 million (Q3 2025), and $58.1 million (Q2 2025) per Business Quant data.